Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma

Inclusion Criteria

• •One prior allograft from an 8/8 or 7/8 allele matched related or unrelated donor, received 60 to 90 days prior to initiation of lenalidomide
• •Meet the diagnostic criteria of symptomatic myeloma at anytime prior to allogeneic HCT
• •Have high-risk multiple myeloma
• •Received ≤ three (3) prior lines of therapy. Prior therapies may include: combination chemotherapy, monotherapy, lenalidomide and autologous HCT. Localized radiation therapy does not count as a single line of therapy. Previous progression on lenalidomide does not exclude participation in the study.
• •Received a reduced intensity conditioning regimen
• •Received or are receiving a GVHD prophylaxis regimen of a calcineurin inhibitor in combination with either methotrexate, mycophenolate mofetil (MMF) or sirolimus
• •Karnofsky performance score ≥ 80 or ECOG ≤ 2
• •There must be at least 50% donor chimerism and no evidence of falling donor chimerism within 1 month of enrollment
• •Laboratory test results within range, within 14 days prior to initiation of lenalidomide
• •All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.